Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IL-15-armored CAR-T in R/R Multiple Myeloma and Plasma Cell Leukemia
NCT07509086Phase 2Recruiting
- Sponsor
- The First Hospital of Jilin University
- Start
- Dec 2025
- Primary completion
- Jul 2028
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in multiple myeloma (MM) and plasma cell leukemia (PCL), sponsored by The First Hospital of Jilin University. Primary endpoint: Overall Response Rate at 12 months. Started Dec 2025; status: recruiting.
02
Conditions
multiple myeloma (MM)plasma cell leukemia (PCL)
Beyond the preview
Go deeper on NCT07509086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07509086.